Lotte Gaasvik

Tell us a bit about your career path so far.

I am a pharmacist by training. After working in the pharmacy in various positions for some years, I transitioned into a role as a Medical Science Liaison (MSL) at a large pharmaceutical company in Sweden. Working in the pharmaceutical industry allows me to leverage my scientific expertise and continue to learn about new data and treatment advancements.

Have you ever worked in a different location?

Yes, I worked in the U.S. as well in Switzerland for many years. Through my role as an MSL in Sweden I met a number of people in global roles and they inspired me to seek out international positions. I love meeting new people and learning about new cultures. Therefore, I took on a global scientific communications role at a large pharmaceutical company. I’m so glad that I did because I grew so much personally and professionally.

What drew you to Oncopeptides?

After working at such a large, multi-national pharmaceutical company, I loved the idea of helping to build the scientific communications function at a start-up. When I joined Oncopeptides there were only about 40 people or so at the Company.

What are you working on?

I lead the development and timely execution of our publication plan based on Oncopeptides' strategy in alignment with a cross-functional team and investigators in our studies, making sure data from our clinical trials gets published at congresses and in scientific journals. I am also leading the development of medical communication material. It’s very exciting, especially since we have so much data coming out!

What makes you proud to work at Oncopeptides?

First of all, we have an unwavering focus on difficult-to-treat hematological diseases. Our work here is so important. Patients suffering with multiple myeloma need new therapies. This is an incurable disease and through our work we can bring them much needed hope. Additionally, as a Swedish citizen I am very proud to work for a Company founded by leading Swedish scientists and headquartered in Stockholm.